As of the latest trading session, Pfizer's stock price is approximately twenty-six dollars and sixty-two cents per share in United States dollars. The trading volume for Pfizer has been around fifty-three million shares, which is relatively consistent with its average volume.

Recently, Pfizer provided its full-year twenty-twenty-five guidance, anticipating revenue to range from sixty-one billion to sixty-four billion United States dollars. The company also expects adjusted diluted earnings per share to be between two dollars and eighty cents and three dollars. This reflects operational growth of ten to eighteen percent compared to the midpoint of its twenty-twenty-four baseline guidance. Pfizer achieved significant cost savings in twenty-twenty-four and expects additional savings in twenty-twenty-five.

Pfizer's strong fourth-quarter twenty-twenty-four results highlighted growth in cancer drugs and Vyndaqel sales, which has been positively received by analysts. Some analysts view Pfizer as undervalued, suggesting its stock price does not fully reflect its true value, particularly for income-focused investors.

In terms of analyst updates, there have been no major changes in price targets recently. However, forecasts for Pfizer's stock price vary, with some predicting a rise to around thirty dollars per share by the end of twenty-twenty-five. Overall, Pfizer remains a significant player in the pharmaceutical industry, with a strong product portfolio and ongoing efforts to improve operational efficiency.

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

This content was created in partnership and with the help of Artificial Intelligence AI